Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly FCF Margin of 912.49% in Q1 2026, up 35.31% quarter-over-quarter from 1410.64% in Q4 2025, and down 85857.0% on a YoY basis from N/an in Q1 2025.
Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' FCF Margin history runs 3 years deep, the most recent figure standing at 912.49% for Q1 2026.
- In Q1 2026, FCF Margin fell 85857.0% year-over-year to 912.49%; the TTM figure through Mar 2026 stood at 381.12% (down 40325.0% YoY), while the FY2025 annual figure was 18.55%, down 7402.0% from the prior year.
- FCF Margin was 912.49% for Q1 2026 at Monte Rosa Therapeutics, up from 1410.64% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 218.77% in Q4 2024 to a low of 3679.32% in Q1 2024.
- Historically, FCF Margin has averaged 756.53% across 3 years, with a median of 232.13% in 2024.
- Biggest YoY gain for FCF Margin was 362540 bps in 2025; the steepest drop was 162941 bps in 2025.
- A 3-year view of FCF Margin shows it stood at 218.77% in 2024, then sank by 745 bps to 1410.64% in 2025, then soared by 35 bps to 912.49% in 2026.
- The last three FCF Margin figures came in at 912.49% (Q1 2026), 1410.64% (Q4 2025), and 66.52% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -912.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -912.49% |
| Dec 31, 2025 | -1,410.64% |
| Sep 30, 2025 | 66.52% |
| Jun 30, 2025 | -162.53% |
| Mar 31, 2025 | -53.92% |
| Dec 31, 2024 | 218.77% |
| Sep 30, 2024 | -232.13% |
| Jun 30, 2024 | -643.02% |
| Mar 31, 2024 | -3,679.32% |